A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

Exclusion Criteria

• •Participants must NOT meet any of the following criteria to be enrolled in this study.
• •1. Received an investigational compound and/or medical device or is part of an investigational study within the past 30 days before enrollment into this study.
• •2. Subject was administered a radioisotope within 5 physical half lives of that radioisotope prior to study enrollment
• •3. Have any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations.
• •4. Participant is determined by the Investigator to be clinically unsuitable for the study.
• •5. Serum creatinine ≥ 2.0 mg/dl
• •6. Total bilirubin ≥ 2.0 mg/dl
• •7. Liver transaminases ≥ 1.5 x ULN
• •8. Platelet count \< 150,000/mm3
• •9. Absolute neutrophil count (ANC) \< 2,000/mm3.
• •10. Hematocrit \< 30% or hemoglobin \< 10 g/dl.
• •11. Abnormal coagulation profile (PT, PTT or INR) \> 1.3 ULN unless on therapeutic anticoagulation.
• •Patients will be excluded from the study if any of the following criteria are observed:
• •i. Androgen deprivation therapy or other forms of hormonal therapy not stable for a period of 14 days prior to screening.
• •ii. Subject has received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants; or 12 months for 125I implants.
• •iii. Subject on or expected to be starting cytotoxic chemotherapy during the study period.
• •iv. Has had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, diagnosis and location must be defined or be defined as clinically controlled or treated to complete response.
• •Healthy Volunteers will be excluded from the study if any of the following criteria are observed:
• •i. Have had any malignancies within 5 years other than basal or squamous cell carcinoma of the skin.
• •ii. History of known prostate adenocarcinoma, prostate surgery/biopsy, prostatitis and/or symptoms suggestive of or associated with possible prostatitis within 6 months of enrollment.